A Phase 1 Study of MRTX0902 in Solid Tumors With Mutations in the KRAS MAPK Pathway

ClinicalTrials.gov ID: NCT05578092

Public ClinicalTrials.gov record NCT05578092. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Sep 3, 2026, 1:52 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 1 Multiple Expansion Cohort Trial of the SOS1 Inhibitor MRTX0902 in Patients With Advanced Solid Tumors Harboring Mutations in the KRAS MAPK Pathway

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

This is a Phase 1, open-label, multicenter, study evaluating the safety, tolerability, PK, PD, and anti-tumor activity of MRTX0902 alone and in combination with MRTX849 (adagrasib) in patients with advanced solid tumor malignancy harboring mutations in the KRAS-MAPK pathways.

Study identification

NCT ID: NCT05578092
Recruitment status: Terminated
Study type: Interventional
Phase: Phase 1
Lead sponsor: Mirati Therapeutics Inc.; Industry
Enrollment: 64 participants

Conditions and interventions

Conditions

Interventions

MRTX0902 Drug
MRTX849 Drug

Drug

Eligibility (public fields only)

Age range: 18 Years and older
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Dec 1, 2022
Primary completion: Feb 2, 2026
Completion: Feb 2, 2026
Last update posted: Feb 18, 2026

2022 – 2026

United States locations

U.S. sites: 17
U.S. states: 13
U.S. cities: 16

Facility	City	State	ZIP	Site status
Local Institution - 001-108	New Haven	Connecticut	06520	—
Local Institution - 001-119	Newark	Delaware	19713-2055	—
Local Institution - 001-111	Orlando	Florida	32827-7400	—
Local Institution - 001-103	Baltimore	Maryland	21287	—
Local Institution - 001-110	Rochester	Minnesota	55905-0001	—
Local Institution - 001-115	Hackensack	New Jersey	07601-2191	—
Local Institution - 001-106	Cincinnati	Ohio	45219-2364	—
Local Institution - 001-109	Portland	Oregon	97239-3011	—
Local Institution - 001-116	Pittsburgh	Pennsylvania	15232	—
Local Institution - 001-101	Nashville	Tennessee	37203	—
Local Institution - 001-102	Nashville	Tennessee	37203	—
Local Institution - 001-112	Dallas	Texas	75246-2003	—
Local Institution - 001-122	Fort Worth	Texas	76104-2154	—
Local Institution - 001-107	Houston	Texas	77030	—
Local Institution - 001-123	Tyler	Texas	75708-3154	—
Local Institution - 001-104	Fairfax	Virginia	22031	—
Local Institution - 001-105	Seattle	Washington	98109	—

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 1 non-U.S. site.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT05578092, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Feb 18, 2026 · Synced Sep 3, 2026

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT05578092 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →